Diverticular Perforation with Normal C-reactive Protein in a Patient with Neuromyelitis Optica Spectrum Disorder Receiving Satralizumab.

Intern MedFeb 10, 2026 (epub)

Miharu Kitazawa, Naoto Osugi, Eri Hayano et al.

✦ AI-curated · Sources linked

Case in brief

A 49-year-old woman with neuromyelitis optica spectrum disorder receiving satralizumab developed mild abdominal pain. Although C-reactive protein had risen transiently earlier in her hospitalization, it was normal when computed tomography showed colonic diverticular perforation with a localized abscess. She improved after percutaneous drainage and targeted antimicrobial therapy. Satralizumab was withdrawn, and she was transitioned to ravulizumab.

What made this case unusual

The perforation and localized abscess were present despite a normal C-reactive protein level during interleukin-6 receptor blockade, potentially obscuring the severity of the abdominal process.

Diagnostic / clinical pearl

In patients receiving interleukin-6 receptor blockade, a normal C-reactive protein level does not exclude complicated diverticulitis; abdominal symptoms may warrant early imaging.

Source

Published in Intern Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.